Familial hypobetalipoproteinemia: genetics and metabolism

Review

DOI: 10.1007/s00018-005-4473-0

Cite this article as:
Schonfeld, G., Lin, X. & Yue, P. CMLS, Cell. Mol. Life Sci. (2005) 62: 1372. doi:10.1007/s00018-005-4473-0

Abstract.

Familial hypobetalipoproteinemia (FHBL), an autosomal dominant disorder, is defined as <5th percentile LDL-cholesterol or apolipoprotein (apo) B in the plasma. FHBL subjects are generally heterozygous and asymptomatic. Three genetic forms exist: (i) premature stop codon specifying mutations of APOB; (ii) FHBL linked to a susceptibility locus on the chromosome 3p21; and (iii) FHBL linked neither to APOB nor to the chromosome 3p21. In heterozygous apoB-defective FHBL, the hepatic VLDL export system is defective because apoB 100, the product of the normal allele, is produced at ∼5% of normal rate, and truncated apoB is cleared too rapidly. The reduced capacity for hepatic triglyceride export increases hepatic fat three-fold. Indexes of adiposity and insulin action are similar to controls. ‘Knock-in’ mouse models of apoB truncations resemble human FHBL phenotypes. Liver fat in the chromosome 3p21-linked FHBL is normal. Elucidation of the genetic basis of the non-apoB FHBL could uncover attractive targets for lipid-lowering therapy. (See note added in proof.)

Key words.

LDL-cholesterol apoB truncation genetics lipoprotein metabolism non-alcoholic fatty liver 

Copyright information

© Birkhäuser Verlag, Basel 2005

Authors and Affiliations

  1. 1.Washington University School of MedicineSt. LouisUSA

Personalised recommendations